Skip to content

Autologous platelet rich plasma (A-PRP) combined with pelvic floor muscle training for the treatment of female stress urinary incontinence (SUI): A randomized control clinical trial

Autologous Platelet rich plasma (A-PRP) combined with pelvic floor muscle training for the treatment of female stress urinary incontinence (SUI): A Randomized control clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230605003
Enrollment
64
Registered
2023-06-05
Start date
2022-11-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence , Famle SUI Stress Urinary Incontinence , Platelet rich plasma

Interventions

Platelet-rich plasma (PRP) is prepared by separating blood into layers using centrifugation with density gradients. Platelet contains numerous growth factors and cytokines, including insulin-like grow
s own blood using centrifugation-based concentration. As long as the preparation is treated with care and sterile approaches, the autologous origin resulted in a satisfactory safety profile for decrea
Active Comparator Drug,No Intervention Behavioral
Autologous Platelet rich plasma,Pelvic floor muscle exercise

Sponsors

Faculty of Medicine Ramathibodi Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnosed SUI by ICIQ UI SF score of 1 to 12 plus 1 hr Pad test more than 1 gram Mild to moderate SUI From ICIQ UI SF score Cough test positive Never received APRP treatment Did not use any SUI treatment procedure within 3 months Never undergone antiincontinence procedures Willing to follow the research protocol follow up Informed consent

Exclusion criteria

Exclusion criteria: OAB Pelvic organs prolapse of anterior compartment Thrombocytopenia Anemia Coagulopathy Pregnancy Urinary retention obesity body mass index more than 35 Urinary tract infection Undiagnosed abnormal vaginal bleeding Taking corticosteroid or immunosuppressants

Design outcomes

Primary

MeasureTime frame
1 hour pad weight test at 1st and 3rd month 1 hour pad weight test

Secondary

MeasureTime frame
IQOL score at 1st and 3rd month IQOL score,ICIQ-FLUT score at 1st and 3rd month ICIQ-FLUT score,PGI score at 1st and 3rd month PGI score,Adverse events at 1st and 3rd month Adverse events

Countries

Thailand

Contacts

Public ContactApisith Saraluck

Ramathibodi

abhisith.13@gmail.com66869616002

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026